Error message

  • Notice: Undefined variable: program_items in dd_program_feature_get_programs_with_keywords() (line 257 of /var/www/public/sites/all/modules/custom/dd_program_feature/dd_program_feature.module).
  • Warning: Invalid argument supplied for foreach() in dd_program_feature_get_replacements() (line 214 of /var/www/public/sites/all/modules/custom/dd_program_feature/dd_program_feature.module).
  • Notice: Undefined index: table in entity_views_plugin_row_entity_view->init() (line 20 of /var/www/public/sites/all/modules/contrib/entity/views/plugins/entity_views_plugin_row_entity_view.inc).

Technology

You are here

Peptides are an increasingly important class of drug. As natural ligands to many targets, they can combine agonistic or antagonistic activity with low toxicity risk and can be applied to disease targets, where small molecules or antibody-based drugs cannot be used. However, the number of therapeutic peptide drugs is held back by properties that are inherent to wild-type peptides. Namely, that they can often bind to multiple receptor subtypes and that the time they remain active in the body is usually very short. Lanthio Pharma’s innovative lanthipeptides overcome these problems and make it possible to discover highly target selective peptides, which only bind and activate one specific target subtype. Importantly, lanthipeptides are more stable than linear wild-type peptides and therefore have much better “drug-like” properties.

Creating receptor-selective peptides

A peptide can have different structural conformations, which can allow it to bind to several different receptors. One conformation is often optimal for binding to one specific receptor. Lanthio Pharma’s technology can be used to make lanthipeptides, which are selective for one specific receptor by constraining them in the optimal structural conformation for binding to that receptor. In this way we have already identified several selective and highly active agonistic peptides for various GPCR targets. This increased target selectivity can open up exciting new therapeutic applications around known disease targets.

Protection against degradation by enzymes in vivo

Peptides can be rapidly degraded by peptidases in the body, limiting their half-life and their therapeutic applicability. Lanthio Pharma’s technology not only constrains peptides in their optimal target binding conformation, the introduction of lanthionines also provides strong protection against peptidase degradation.

Bacterial lanthi-peptide production

We use Lactococcus lactis and Escherichia coli bacteria to produce peptides of therapeutic interest. The lanthipeptide enzyme system introduced into the bacteria is triggered to introduce one or more thioether bridges in specific locations in these peptides. Once the thioether bridges are formed, the lanthipeptides can be transported out of the Lactococcus bacteria into the extracellular medium to be easily purified, or harvested after intracellular production in E. coli.

Bacterial lanthipeptide display

When genetically fused to an anchor sequence, exported lanthipeptides can be covalently fixed to the Lactococcus cell wall to be displayed as a lanthipeptide display library.

Phage display of lanthipeptides

Recently, phage display of lanthipeptide libraries and selection have been established by MorphoSys and Lanthio Pharma (Nature Communications 2017 in press).

  • Lanthionines are dehydrated serines or threonines, coupled to a cysteine via a thio-ether bond resulting in D,L Ala-S-Ala or Abu-S-Ala.
  • Lanthipeptides are enzymatically produced in Lactococcus lactis or in Escherichia coli bacteria.
  • Improved rigidity of the peptide’s receptor-binding-region may enable optimal interaction between the stabilized peptide and its receptor. For example, stabilization of turn motifs in peptides for GPCR targets allows discovery of highly target specific and active lanthipeptides.
  • The technology produces isomerically pure peptides with designed lanthionines in one or more specified positions in the peptide.